Therefore, PRRX1 was not only considered a potential biomarker for predicting patient outcomes and disease progression but also a potential therapeutic target that could be inhibited by targeted therapy to suppress tumor growth and metastasis (102). This evidence concerns the gene PRRX1 and neoplasm.